Effect of pitavastatin on cholesterol efflux to apoA-I (20 μg/ml) from MPMs pretreated with cpt-cAMP, 22OH-cRA, or AcLDL
Experimental conditions are as in the legends to Figs. 1 and 3.
cpt-cAMP (0.3 mM) | AcLDL (50 μg/ml) | 22OH (5 μg/ml)-cRA (10 μM) | ||
|---|---|---|---|---|
| % cholesterol efflux | ||||
| Control | 6.3 ± 0.8 | 7.4 ± 0.8 | 8.2 ± 0.8 | |
| Compactin, 10 μM | 4.4 ± 0.8* | 6.3 ± 1.6(N.S.) | 7.0 ± 0.3(N.S.) | |
| Pitavastatin, 10 μM | 4.7 ± 0.4* | 6.6 ± 0.7(N.S.) | 7.3 ± 1.0(N.S.) | |
N.S., not significant versus control.
↵* p < 0.05 compared with control.